Arizona has an opioid problem. It also has a methamphetamine problem that gets far less attention — and in some ways is harder to treat, because unlike opioid use disorder, there is no FDA-approved medication for stimulant use disorder. In 2024, methamphetamine was involved in roughly 60% of Arizona's overdose deaths — on the order of 1,655 meth-related deaths. Yet the treatment with the strongest evidence behind it remains chronically underused.
That treatment is contingency management (CM). If you counsel people who use stimulants, it deserves a much bigger place in your toolkit.
Why meth is different
For opioid use disorder, we have medications — buprenorphine, methadone, naltrexone — with decades of evidence. For stimulant use disorder, that pharmacological toolbox is essentially empty. There's no approved medication that reliably reduces meth use.
That's not a small gap. It means the burden of treatment falls on behavioral interventions — and among those, one stands out in the research literature.
What contingency management is
Contingency management is deceptively simple: it provides tangible, immediate rewards for verified abstinence or treatment engagement. A client who submits a drug-negative test, or hits an agreed-upon treatment milestone, earns a reward — often escalating in value the longer they sustain progress.
The mechanism is rooted in behavioral science: addiction hijacks the brain's reward system toward the substance, and CM re-introduces competing, immediate, positive reinforcement for the behaviors that support recovery. It's not a gimmick or a bribe — it's the systematic application of one of the most robust principles in behavioral psychology.
And the evidence is strong. Across study after study, CM is one of the most effective interventions we have for stimulant use disorder — arguably the most effective, given the absence of a medication alternative.
So why don't we use it more?
If CM works this well, the obvious question is why it isn't everywhere. The barriers are real but solvable:
- Reimbursement. Historically, many payers didn't cover the incentives themselves, and rules about the value of incentives (partly rooted in fraud-and-abuse concerns) constrained programs. This landscape has been loosening, but it still creates hesitation.
- Cultural resistance. "Paying people to be sober" runs against a moral intuition some clinicians and communities hold. That intuition, however well-meaning, isn't supported by the outcomes data.
- Operational complexity. Running CM well requires reliable testing, prompt reward delivery, and fidelity to the protocol. Done sloppily, it doesn't work — which sometimes gets misread as the method not working.
None of these is a reason to leave the most effective stimulant treatment on the shelf. They're implementation problems, and implementation problems have solutions.
Making CM work in practice
If you want to bring CM into your program, a few principles matter:
- Immediacy is everything. The reward has to closely follow the verified behavior. Delayed rewards lose most of their power.
- Verification has to be solid. CM depends on trustworthy confirmation of abstinence or engagement.
- Escalation helps. Rewards that increase in value with sustained progress reinforce longer streaks of recovery.
- Pair it with the rest of care. CM isn't a standalone cure — it's a powerful engine that works best alongside counseling, peer support, and wraparound services.
The peer-support connection
CM pairs especially well with peer support. In Arizona, peer roles are a reimbursable, growing part of the workforce, and combining lived-experience support with the structured reinforcement of CM can be more powerful than either alone. Emerging models are actively testing peer-delivered CM, and the logic is sound: a peer who understands the client's world, plus a structure that rewards each step forward, is a formidable combination.
Why this matters for Arizona right now
While national overdose deaths have been falling, Arizona's have been rising — and stimulants are a major part of that story. This isn't only a fentanyl crisis; it's increasingly a polysubstance crisis, with meth involved in a large share of deaths. That makes an effective stimulant treatment more urgent in Arizona than in many other states. CM is the tool the evidence points to, and Arizona's crisis is exactly the kind that CM is built to address.
The takeaway
There's no medication for meth addiction — but there is a treatment with genuine evidence behind it, and too many programs still don't offer it. Contingency management systematically rewards verified abstinence and engagement, and for stimulant use disorder it's among the most effective interventions we have. In a state where meth drives a large share of overdose deaths and total deaths are climbing, leaving CM on the shelf is a choice Arizona can't afford. If you're not using it, it's worth learning how.
This article is for general educational purposes and reflects clinical evidence and Arizona overdose data available as of early 2026 (figures are provisional and subject to revision). It is not clinical or legal advice. Implement contingency management in accordance with current evidence-based protocols and applicable regulations.
